MedDataX Logo

Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

NCT ID: NCT00531635

Last Updated: 2011-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-07-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Induction of mixed hemopoietic chimerism in patients using Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA \& Mycophenolate Mofetil

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Mixed hemopoietic chimerism, Fludarabine, TBI, PBSC, immunosuppression, Mycophenolate Mofetil

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mycophenolate Mofetil

Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients receiving Fludarabine, Low Dose TBI, PBSC Infusion and post transplant in immunosuppression w/CSA \& Mycophenolate Mofetil.

Exclusion Criteria

* Uncontrolled major medical illnesses
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King Faisal Specialist Hospital & Research Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mahmoud Aljurf, MD

Role: PRINCIPAL_INVESTIGATOR

KFSH&RC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KFSH&RC

Riyadh, , Saudi Arabia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mahmoud AlJurf, MD

Role: CONTACT

Phone: 966-1-4647272

Email: [email protected]

Ed Colcol

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mahmoud Aljurf, MD

Role: primary

Ed Colcol

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAC#2001-051

Identifier Type: -

Identifier Source: org_study_id